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Abstract
Background: The overlap syndrome of primary biliary cholangitis (formerly called primary biliary cirrhosis) and
primary sclerosing cholangitis is an extremely rare condition that has never been described in association with
other immune-mediated diseases, including psoriatic arthritis. While treatment with anti-Tumour Necrosis
Factor-alpha (TNF-α) agents has proved to be effective in inflammatory arthropathies such as psoriatic arthritis,
they have been employed in only a limited number of patients with autoimmune hepatitis, and their effectiveness
is unclear.
Case presentation: We report the case of a 51-year-old female affected with psoriatic arthritis concomitant to
overlapping primary biliary cholangitis and primary sclerosing cholangitis in whom 28 months of adalimumab
treatment improved the symptoms of the inflammatory arthropathy as well as those of both cholangiopathies.
Conclusion: Our results suggest that further studies examining the therapeutic role of this particular TNF-α blocker
are warranted in cholestatic autoimmune hepatitis patients, and in particular in those individuals in whom the
disease is associated with inflammatory arthropathies.
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Background
While a variety of immunological diseases, including
rheumatoid arthritis (RA), have been reported in patients
affected by primary biliary cholangitis (formerly called pri-
mary biliary cirrhosis) (PBC) [1], primary sclerosing chol-
angitis (PSC) is strongly associated with inflammatory
bowel disease (IBD), and particularly with ulcerative colitis
(UC) [2]. Until now only one case of a psoriatic arthritis
(PsA)-PBC association has been reported [3], and, to the
best of our knowledge, no cases of PsA associated to PSC
have ever been described in the literature. The PBC-PSC
overlap syndrome is, moreover, an extremely rare condi-
tion that has been described in only eight cases [4].
The development of Tumour Necrosis Factor-α (TNF-α)
blockers has represented a milestone in the treatment of
inflammatory joint diseases. Adalimumab, which is a fully
human anti-TNF-α monoclonal antibody, has been shown
to be effective in achieving remission and in preventing
radiographic progression of joint damage in patients with
RA and other inflammatory arthropathies, including PsA. It
has also been found to be efficacious in treating skin and
nail lesions in PsA patients [5]. Although a pathogenic
hypothesis [6, 7] would justify the use of anti-TNF-α drugs
for both PBC and PSC, treatment outcome is nevertheless
uncertain. A double-blind, placebo-controlled, randomized
study examining Infliximab treatment in PSC patients con-
cluded that it was inefficacious in the small group studied
[8]. It was likewise ineffective in a case of PBC associated
with RA [9], although it did prove to be efficacious in a case
of PSC that was complicated by ankylosing spondylitis and
UC [10]. Etanercept led to an improvement in both liver
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enzymes and arthritis in two cases of RA associated
with PBC [9, 11]. Prescribed to treat IBD in a patient
who was also suffering from PBC, Adalimumab treatment
led to a favourable clinical and laboratory response with
regard to both disorders [12]. To date, no cases of PBC,
PSC, or overlapping PBC-PSC associated with inflamma-
tory arthropathies have been treated with Adalimumab.
The current report describes a case in which Adalimumab
treatment led to clinical improvement in arthritis
symptoms and in nail lesions and also lowered chole-
stasis indices in a PsA patient with overlapping PBC-
PSC syndrome.
Case presentation
In September 2011 a 51-year-old Caucasian woman with
a history of psoriasis and type-2 diabetes mellitus devel-
oped a mild psoriasis together with dactylitis affecting
the right fourth finger and arthritis of the fourth meta-
carpophalangeal (MCP) joint of the right hand. In
November 2011 she was referred our outpatient clinic.
Dactylitis of the fourth finger of the right hand and
swelling, redness and pain of the distal interphalangeal
(DIP) joint of the second digit of the right hand were
noted during the physical examination. Laboratory results
at that time included: Erythrocyte sedimentation rate
(ESR) = 100 mm/h (normal range 0–39 mm/h), C-reactive
protein (CRP) = 3.99 mg/l (normal range 0–6 mg/l),
gamma-glutamyltransferase (γGT) = 237 IU/l (normal range
3–45 IU/ml), and alkaline phosphatase (ALP) = 201 IU/l
(normal range 53–141 IU/ml). The patient was treated with
methylprednisolone for 6 months; treatment was started
with doses of 16 mg/die that were tapered to 4 mg/die. She
also received 15 mg weekly oral Methotrexate (MTX) for
6 months beginning in May 2012 with poor results. In
March 2012, hand X-rays uncovered periostitis of the
proximal phalanx of the right fourth digit; ultrasound
(US) and powerdoppler evaluation revealed flexor teno-
synovitis of the fourth finger of the right hand and a
small erosion in the head of the fourth MCF of the
right hand. An US-guided corticosteroid injection of
the tendon sheath was adminstered.
In April 2012 the patient presented to the Gastroenter-
ology Unit of the University of Padova Medical Centre. Bio-
chemical testing confirmed abnormal cholestatic patterns
that had been persisting since 2009 (γGT 229 IU/ml and
ALP 201 IU/ml). At that time the patient showed: antimito-
chondrial antibody (AMA) positivity in immunofluores-
cence with a 1:160 titre, immunoblotting positivity for M2,
3E and anti pg 210, total serum cholesterol = 240 mg/dl
(range ≤ 200 mg/dl), serum IgM= 7.31 g/L (range 0.4–
2.38 g/L), normal transaminases, negative hepatitis B and C
serum markers. The patient showed no symptom of chole-
stasis; the liver and spleen were not palpable. A liver biopsy,
which was performed in May 2012, showed marked fibrosis
of the portal tracts extending to the parenchyma, interface
hepatitis, and a vanishing bile duct picture with the
remaining ducts showing regressive alterations of cholan-
giocytes together with biliary metaplasia. The histological
picture was compatible with stage III PBC. Ursodeoxycholic
acid (UDCA), which was begun in April 2012 at 10 mg/Kg/
day, was later increased to 15 mg/Kg/day; a partial re-
duction in γGT and ALP was recorded. In July 2012, the
patient underwent Magnetic Resonance Imaging (MRI)
cholangiography of the upper abdomen which revealed a
marked reduction of the right segmental duct extended
for 2.5 cm, with upstream dilatation, and pronounced
stenosis of the biliary tree in the 5th and 6th hepatic seg-
ment considered characteristic of PSC. MRI typically
shows multiple strictures and dilatations of the intrahepa-
tic biliary tree in PSC patients. In our case, the coexistence
of a liver biopsy compatible with PBC and MRI results
typical of PSC permitted us to formulate a diagnosis of
PBC-PSC overlap syndrome.
Given the absence of both the histopathological features
of IgG4-related disease and abundant IgG4+ plasma cells in
the liver biopsy material, the hypothesis of IgG4-associated
cholangitis was excluded. Furthermore, there were no signs
of synchronous involvement of other organs.
In October 2012, arthritis of the fourth right DIP joint
and severe nail psoriasis were two new symptoms that
were added to the clinical picture (Fig. 1a). Hand X-rays
showed new erosions in the fourth right MCF and DIP
(Fig. 1b). Adalimumab treatment (40 mg fortnightly),
which was begun at that time, led to notable relief of the
pain and stiffness. Three months later the painful swell-
ings of the second and fourth right DIP joints showed
marked improvement, and the nail of the fourth right
finger appeared normal (Fig. 2a). The patient’s Health
Assessment Questionnaire (HAQ) disability index score
fell from 0.750 to 0.375, the Disease Activity Score 28
(DAS28) fell from 4.25 to 3.18 and the Disease Activity
in Psoriatic Arthritis (DAPSA) score fell from 17.37 to
4.29. Liver function tests improved, the ALP normalized,
and the γGT and IgM improved (respectively falling to
124 IU/L and 5.35 g/L). Twelve months later, the HAQ
continued to fall reaching 0.25, the DAS 28 fell to 1.80,
and the DAPSA to 2.69. Hand X-rays showed that the
bone erosion infourth right DIP joint seemed to have
disappeared while the erosion at the base of the first
phalanx persisted (Fig. 2b). Unfortunately, we do not
have Computerized Tomography (CT) or MRI confirm-
ation of these findings. Twenty-eight months later, the
patient’s HAQ and DAS 28 values were stable, the
DAPSA was 5.29 (low disease activity), the γGT and
serum IgM had fallen even further (respectively reaching
98 IU/ml, and 4.93 g/L), and the ALP remained at normal
levels (107 IU/ml) (Fig. 3). At present, the patient
continues to receive Adalimumab and enjoys good health.
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Discussion
The current report describes for the first time a patient
affected with PsA as well as with an overlapping PBC-
PSC syndrome who was treated with Adalimumab which
led to a clinical improvement in arthritis symptoms and
lowered the indexes of cholestasis.
A recent study demonstrated a strong positive correl-
ation of 44 non-human leukocyte antigen (HLA) loci for
PSC that were also identified in seven immunological
disorders including psoriasis [13]. In addition, suscepti-
bility to PSC may be determined by polymorphisms of
TNF genes [14]. The existence of TNF-α gene promoter
variants that act as markers of both disease severity
and response to treatment has been hypothesized for
inflammatory arthropathies. The main TNF-α and TNF-α
receptor polymorphisms also seem to be able to predict
response to TNF-α blockers in PsA patients [15, 16]. As
genetic factors play an important role in anti-TNF-α re-
sponse in inflammatory arthropathies, it could be argued
that they influence the effect of anti-TNF-α treatment in
autoimmune colangiopathies or at least in some clinical
phenotypes. It is also possible that different genetic combi-
nations predispose patients to a particular clinical pheno-
type influencing response to treatment.
In the case outlined here in which PsA was associated
with an overlapping PBC-PSC syndrome, the patient’s
good response to TNF-α blockers seems to confirm the
important role of TNF-α in the pathogenesis of these
diseases. In addition, the fact that some TNF-α blockers
are effective in different cholestatic autoimmune liver
Fig. 2 Right hand:swelling of the fourth distal interphalangeal joint was markedly improved, and nail appeared normal (a). Radiograph of the
right hand: the bone erosion in the fourth distal interphalangeal joint seemed to have disappeared (b)
Fig. 1 Right hand: arthritis of the fourth distal interphalangeal joint with severe nail psoriasis (a). Radiograph of the right hand: erosions in the
fourth metacarpophalangeal and distal interphalangeal joints (b)
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diseases in the presence of an inflammatory arthropathy
is a particularly interesting, thought-provoking finding
[9–12].
Adalimumab also proved to be effective in the case
studied, even in connection to the radiographic alter-
ations (bone erosions in the fourth right DIP) which
seemed to disappear (Fig. 2b). It is nevertheless possible
that the marked improvement in the patient’s bone condi-
tion was linked to the precocious therapeutic intervention
that was implemented.
Conclusion
Concomitant autoimmune diseases and/or immune-
mediated disorders, which share genetic basis and possibly
similar molecular pathways, have frequently been found in
the same patient. As genetic factors play a vital role in the
susceptibility to inflammatory arthropathies and in de-
termining a drug’s effect, they may also be involved in
the development of autoimmune colangiopathies and/or
of some clinical phenotypes. A TNF-α polymorphism may
explain both TNF-α’s pathogenic role in clinical subsets as
well as the response to TNF-α blockers. In the case de-
scribed here, the concomitant presence of PsA and the
PBC-PSC overlap syndrome as well as the patient’s good
response to TNF-α blockers all seem to confirm a com-
mon pathogenesis and point to the hypothesis that the use
of anti-TNF-α drugs could be effective in one or more
subsets of autoimmune colangiopathies. Notably, the clin-
ical phenotype of the autoimmune colangiopathies that re-
spond favorably to anti-TNF-α drugs seems to be the one
in which inflammatory arthropathy is also present, as has
been reported by our as well as other research groups.
Future studies will be able to verify the efficacy of TNF-α
blockers in autoimmune cholangiopathies associated to
inflammatory arthropathies and to identify the clinical
subsets that are responsive to different anti-TNF-α agents.
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